

# IN THE SPOTLIGHT

Issue 83 | Mar-Apr 2021

## NEWS & ACHIEVEMENTS



### NUS Medicine Awards 2020

Congratulations to Dr. Teoh Phaik Ju and Dr. Chong Shu Yun Phyllis, who were honoured for their research achievements at the NUS Medicine Awards 2020 Ceremony. The award ceremony recognises and celebrates the success and efforts of its employees' outstanding commitment and contributions to research, teaching and mentorship.

[read more >>>](#)



### CSI Research Fellow Receives International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Career Development Award

Congratulations to Dr. Teoh Phaik Ju, Research Fellow from Prof. Chng Wee Joo's lab, who has recently been awarded the prestigious International Myeloma Society (IMS) and Paula and Rodger Riney Foundation Career Development Award for her outstanding research proposal. Moving forward, the award will fund Dr. Teoh's work on a myeloma project with collaborators from the Dana-Farber Cancer Institute in Boston, Massachusetts.

[read more >>>](#)



### [Listen] Health Matters - Improving Treatment Outcomes for Breast Cancer

In this interview on radio station CNA938's "Health Matters with Daniel Martin", Prof. Lee Soo Chin shares how her recent study will offer a solution to restore sensitivity to anti-HER2 treatment, which may help alter the treatment paradigm for breast cancer patients.

[read more >>>](#)

### Identification of a Targetable KRAS-Mutant Epithelial Population in Non-Small Cell Lung Cancer. (*Commun Biol*, Apr 2021)

In this study on lung cancer, Prof. Daniel Tenen and his team identified a tumour subpopulation uniquely present in K-RAS Non-Small cell Lung Cancers (NSCLC). By investigating the effects of in vivo PTC596 treatment, findings revealed a reduction in tumour growth, underscoring the therapeutic potential of PTC596 in the treatment of KRAS mutant Non-Small Cell Lung Cancers (NSCLC).



[read more >>>](#)

### Quantitative Imaging of RAD51 Expression as a Marker of Platinum Resistance in Ovarian Cancer. (*EMBO Mol Med*, Mar 2021)

Epithelial ovarian cancer (EOC) is the most common cause of gynaecological cancer death. While platinum chemotherapy is the standard treatment of ovarian cancer, not all patients are receptive to it. Findings from a study helmed by A/Prof. David Tan and Dr. Anand Jeyasekharan present useful information on the therapeutic potential of RAD51 as a biomarker to determine the resistance of an ovarian cancer patient to platinum chemotherapy. Furthermore, the group established that RAD51 can be further explored for use in routine diagnostic practice to identify platinum-resistant ROC patients.



[read more >>>](#)

### Prolonged Maintenance of Hematopoietic Stem Cells that Escape From Thrombopoietin Deprivation. (*Blood*, Mar 2021)

Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), the International Research Center for Medical Sciences (IRCMS) at the Kumamoto University and the Tokyo Women's Medical University (TWMU) unravelled novel insights on hematopoietic stem cell (HSC) maintenance and its mechanism under thrombopoietin (Thpo) deficiency. The team, which includes Prof. Toshio Suda and Dr. Ayako Ishizu, established that Thpo signalling elicits wide-ranging response in HSCs.



[read more >>>](#)



Cancer Science Institute of Singapore  
National University of Singapore  
Centre for Translational Medicine  
14 Medical Drive, #12-01  
Singapore 117599